Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Hyperglycemia 2Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Breast Neoplasms 1

Interventions

Insulin Glargine 4Insulin 3Alpelisib 3volagidemab 2Metformin 2Fulvestrant 2ziprasidone 1relacorilant 1pembrolizumab 1olaparib 1exemestane 1dapagliflozin 1Vildagliptin 1Tamoxifen 1Standard of Care 1Olanzapine 1Letrozole 1Insulin Lispro 1Insulin Aspart 1Injections 1Electrocardiography 1DNA, Ribosomal 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hyperglycemia × volagidemab × Clear all
NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated
1 enrolled
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04253223 2021-06-11

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Duke University

Phase 1 Terminated
1 enrolled
Lymphoid

Hyperglycemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡